Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cholecystokinin A receptor | Starlite/ChEMBL | References |
Homo sapiens | cholecystokinin B receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Brugia malayi | sulfakinin receptor protein | Get druggable targets OG5_132882 | All targets in OG5_132882 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | rhodopsin orphan GPCR | cholecystokinin A receptor | 428 aa | 373 aa | 19.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | SET domain-containing protein | 0.8956 | 0.5 | 0.5 |
Echinococcus granulosus | histone lysine N methyltransferase Ez | 0.8956 | 0.5 | 0.5 |
Schistosoma mansoni | enhancer of zeste ezh | 0.8956 | 0.5 | 0.5 |
Echinococcus multilocularis | histone lysine N methyltransferase E(z) | 0.8956 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 42 % | Compound tested in vivo for mouse gallbladder emptying at 10 microM/kg, po | ChEMBL. | 8709137 |
Activity (functional) | = 42 % | Compound tested in vivo for mouse gallbladder emptying at 10 microM/kg, po | ChEMBL. | 8709137 |
Activity (functional) | = 45 % | Compound tested in vivo for mouse gallbladder emptying at 1.0 microM/kg, po | ChEMBL. | 8709137 |
Activity (functional) | = 45 % | Compound tested in vivo for mouse gallbladder emptying at 1.0 microM/kg, po | ChEMBL. | 8709137 |
Activity (functional) | = 68 % | Compound tested in vivo for mouse gallbladder emptying at 0.1 microM/kg, ip | ChEMBL. | 8709137 |
Activity (functional) | = 68 % | Compound tested in vivo for mouse gallbladder emptying at 0.1 microM/kg, ip | ChEMBL. | 8709137 |
ED50 (functional) | = 0.78 uM | In vitro agonist activity against Cholecystokinin type A receptor isolated from guinea pig gall bladder. | ChEMBL. | 8709137 |
ED50 (functional) | = 0.78 uM | In vitro agonist activity against Cholecystokinin type A receptor isolated from guinea pig gall bladder. | ChEMBL. | 8709137 |
IC50 (binding) | = -7.44 | Binding affinity against human Cholecystokinin type A receptor in membrane prepration isolated from CHO-K1 cells stably transfected with cDNA of human CCK-A using [125I]-Bolton-Hunter CCK-8 as radioligand | ChEMBL. | 8709137 |
IC50 (binding) | = -6.1 | Binding affinity against human Cholecystokinin type B receptor in CHO-K1 cells using [125I]-Bolton-Hunter CCK-8 as radioligand | ChEMBL. | 8709137 |
Log IC50 (binding) | = 6.1 | Binding affinity against human Cholecystokinin type B receptor in CHO-K1 cells using [125I]-Bolton-Hunter CCK-8 as radioligand | ChEMBL. | 8709137 |
Log IC50 (binding) | = 7.44 | Binding affinity against human Cholecystokinin type A receptor in membrane prepration isolated from CHO-K1 cells stably transfected with cDNA of human CCK-A using [125I]-Bolton-Hunter CCK-8 as radioligand | ChEMBL. | 8709137 |
Ratio (binding) | = 22 | Selectivity ratio of IC50 of CCK-B to IC50 of CCK-A | ChEMBL. | 8709137 |
Ratio (binding) | = 22 | Selectivity ratio of IC50 of CCK-B to IC50 of CCK-A | ChEMBL. | 8709137 |
RE (functional) | = 0.6 | Relative efficacy of the compound determined by the maximal contraction observed at 30 microM ,standardized to CCK-8 | ChEMBL. | 8709137 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.